Search

A recent study found that parental use of e-cigarettes was associated with an increased risk of atopic dermatitis (AD) in children. The study analyzed data from the National Health Interview Survey and found that the prevalence of parental e-cigarette use was higher among individuals with AD compared to those without AD. The study concluded that parental e-cigarette use was associated with pediatric AD, and previous research has suggested that the inflammatory state caused by e-cigarettes may be the cause. However, it is important to note that the study's design limited the ability to draw causal inferences. [Extracted from the article]

Clinicians should use one of three validated instruments to measure signs of atopic dermatitis (AD) in their clinical practice, according to a consensus statement published in JAMA Dermatology. The recommended instruments are the Eczema Area and Severity Index (EASI), the Validated Investigator Global Assessment for AD (vIGAAD), and the Investigator's Global Assessment (IGA) combined with a body surface area (BSA) assessment. The statement was based on a systematic review conducted by the Harmonizing Outcome Measures for Eczema Clinical Practice initiative. The authors acknowledged that the EASI may be challenging to use, but studies have shown that completion times can be as low as two minutes with trained investigators. [Extracted from the article]

A retrospective study of almost 800 patients aged 60 years and older with atopic dermatitis (AD) found that the condition most commonly presented on the extensor surfaces and trunk, with lichenification and nummular lesions being the most frequent rash characteristics. The study also revealed that the use of topical corticosteroids was the most common treatment, followed by oral corticosteroids and antihistamines. The researchers noted that AD in older individuals presents as a unique phenotype compared to younger ages, which may inform dermatologists' diagnosis and treatment of AD in this population. Further research is needed to understand the specific features and optimal treatments for AD in older patients. [Extracted from the article]

Clinicians should use validated instruments to measure signs of atopic dermatitis (AD) in their clinical practice, according to a consensus statement published in JAMA Dermatology. The recommended instruments include the Eczema Area and Severity Index (EASI), the Validated Investigator Global Assessment for AD (vIGAAD), and the Investigator's Global Assessment (IGA) combined with a body surface area (BSA) assessment. The statement was based on a systematic review conducted by the Harmonizing Outcome Measures for Eczema Clinical Practice (HOME-CP) initiative. The authors acknowledged limitations in their recommendations, including the lack of input from primary care clinicians. [Extracted from the article]

Recent advances in treatments for atopic dermatitis (AD) have influenced the interventions used by dermatologists when treating children with AD, according to Dr. Lawrence F. Eichenfield. He discussed the "tried and true" approaches to care for patients with persistent eczema, including the use of moisturizers/emollients, bathing, bleach baths, and topical corticosteroids. Dr. Eichenfield also highlighted the importance of measuring outcomes and familiarizing oneself with nonsteroidal anti-inflammatory medications for care regimens. He encouraged dermatologists to share information and experiences with evolving treatment options for AD. [Extracted from the article]

A 10-year observational study has found that moderate to severe atopic dermatitis can reduce linear growth in children under 12 years old. The study, called PEDISTAD, enrolled 1326 children with inadequately controlled atopic dermatitis and assessed their height, weight, and body mass index (BMI) against population norms. The results showed that a smaller percentage of children with atopic dermatitis were above the 50th percentile for height compared to weight and BMI. The study's author, Dr. Amy S. Paller, noted that factors such as chronic inflammation, poor sleep, and the use of steroids may contribute to the reduction in linear growth. The study also highlighted the need for further research on the impact of treatment and early intervention on growth in children with atopic dermatitis. [Extracted from the article]

A recent study has found that children who develop atopic dermatitis (AD) in early childhood have an increased risk of developing inflammatory bowel disease (IBD) later in life. The study analyzed data from two cohort studies, following over 83,000 children from birth until 2021 or a diagnosis of IBD. The findings showed that children with AD at the age of 3 had a significantly higher risk of developing IBD, Crohn's disease, and ulcerative colitis. The researchers suggest that these findings could help identify individuals at risk and lead to the development of novel treatment approaches for both conditions. However, it is important to note that the study focused on childhood-onset IBD and may not be fully generalizable to the broader population. [Extracted from the article]

A phase 3 study presented at the American Academy of Dermatology's annual meeting found that treatment with topical roflumilast, 0.05%, showed high levels of improvement in about a quarter of children aged 2-5 years with mild to moderate atopic dermatitis (AD). The study included 652 patients, with 437 assigned to roflumilast cream and 215 assigned to a vehicle cream. The results showed that 25.4% of patients treated with roflumilast reached the primary endpoint of "clear" or "almost clear" plus a two-grade improvement from baseline at week 4, compared to 10.7% in the vehicle group. The study also found that itch improved within 24 hours of starting treatment. Safety data showed that 29.7% of patients taking roflumilast had treatment-emergent adverse effects, compared to 21.9% in the vehicle arm. Dermatologists believe that topical roflumilast could be an important new treatment option for children with AD, as there are currently few nonsteroidal options available. [Extracted from the article]

A recent study published in JAMA Dermatology suggests that children with atopic dermatitis may have an increased risk of cognitive impairment, particularly if they have neurodevelopmental disorders like ADHD or a learning disability. The study analyzed data from the 2021 US National Health Interview Survey and found that children with atopic dermatitis were more likely to experience difficulties with learning and memory compared to those without the condition. The association remained even after adjusting for factors like asthma, food allergies, and seasonal allergies. The researchers recommend prioritizing evaluation for cognitive impairment in children with atopic dermatitis and comorbid ADHD or learning disability. However, the study's limitations include its cross-sectional design and reliance on caregiver reports. [Extracted from the article]

A phase 3b trial has shown that lebrikizumab, a monoclonal antibody developed by Eli Lilly and Co, is effective in treating moderate to severe atopic dermatitis (AD) in patients with darker skin tones. In the study, 68% of patients achieved a 75% reduction in the Eczema Area and Severity Index (EASI-75) after 16 weeks of treatment. The trial is significant because there is a lack of data on the treatment of AD in populations traditionally underrepresented in clinical trials, including patients with skin of color. Lebrikizumab was approved in Europe for the treatment of moderate to severe AD and is currently under review by the FDA. [Extracted from the article]

Dermavant Sciences has submitted a supplemental New Drug Application (sNDA) to the FDA for tapinarof cream, 1%, to treat atopic dermatitis (AD) in adults and children aged 2 and older. Tapinarof cream is already approved for treating plaque psoriasis in adults. The sNDA is based on positive data from phase 3 trials, which showed statistically significant improvements in the primary endpoint of Validated Investigator Global Assessment for Atopic Dermatitis (vIGA-AD) treatment success. The most common adverse reactions to tapinarof cream include folliculitis, nasopharyngitis, contact dermatitis, headache, and pruritus. [Extracted from the article]

Galderma has announced that the FDA has accepted its Biologics License Application for nemolizumab, a monoclonal antibody, for the treatment of prurigo nodularis and moderate to severe atopic dermatitis in adolescents and adults. Nemolizumab has also been granted FDA Priority Review for prurigo nodularis. The European Medicines Agency has accepted Galderma's Marketing Authorization Applications for both indications as well. These regulatory developments are based on data from the phase III OLYMPIA clinical trial program, which showed significant improvements in itch intensity and skin lesions in patients treated with nemolizumab compared to placebo. [Extracted from the article]

The article highlights the remarks by Dr. David Rosman at the Revolutionizing Atopic Dermatitis (RAD) Virtual Conference about atopic dermatitis (AD) biologic therapies in development. AD biologic therapies he highlighted include CM310 from Stapokibart, Eblasakimab which is under development by ASLA Pharmaceuticals, and Amlitelimab under development by Sanofi.

An experimental topical drug called PF-07038124, developed by Pfizer, has shown promise in treating mild to moderate atopic dermatitis (AD) and plaque psoriasis. The drug is a phosphodiesterase 4 (PDE4) inhibitor, which can reduce the production of proinflammatory cytokines. In a phase 2a study, patients who received PF-07038124 showed significantly greater improvement in their symptoms compared to those who received a placebo. The drug was well-tolerated and did not cause any adverse reactions at the application sites. However, the study had limitations, and further research is needed to confirm the drug's long-term efficacy and safety. [Extracted from the article]

In an article from Pediatric News titled "Expert Frames Factors to Consider Among Atopic Dermatitis Treatment Options," Dr. Raj Chovatiya discusses the challenges dermatologists face when choosing the right therapy for patients with atopic dermatitis (AD). He emphasizes that there is no one-size-fits-all approach and that it may be difficult to compare different treatment options. Dr. Chovatiya provides a list of factors to consider when making treatment decisions, including disease severity, drug onset, response depth, long-term efficacy, adverse events, black box warnings, tolerance, vehicle, patient preference, and drug accessibility. He also raises the question of whether a topical steroid-free world for AD is desirable and highlights the progress made in targeted therapy. Dr. Chovatiya discloses his affiliations with pharmaceutical companies. [Extracted from the article]

A recent analysis of registry data supports the effectiveness of the oral Janus kinase inhibitor upadacitinib in treating moderate-to-severe atopic dermatitis (AD). The study found that over half of the patients treated with upadacitinib achieved clear or almost clear skin, and more than 45% reported no or minimal itch. The analysis evaluated real-world clinical and patient-reported outcomes of 335 adults enrolled in the CorEvitas AD Registry. The findings suggest that upadacitinib is effective in reducing disease severity in a real-world setting, confirming the results of clinical trials. [Extracted from the article]

The article explores the efficacy of lebrikizumab, an interleukin-13 inhibitor, in treating moderate-to-severe atopic dermatitis across different racial and ethnic subgroups. The study presented findings from the 16-week induction periods of the phase 3 ADvocate1 and ADvocate2 trials, indicating significant effectiveness in diverse populations, although additional studies are needed for verification.

Tapinarof cream has been found to be highly effective, safe, and well tolerated for the treatment of atopic dermatitis (AD) in both adults and children as young as 2 years old. The cream, which is an aryl hydrocarbon receptor agonist, was approved in 2022 for treating plaque psoriasis in adults. In two phase 3 trials, tapinarof cream demonstrated significant improvement in AD symptoms compared to a control group, with response rates for clear or almost clear skin and 75% clearance of skin lesions being much higher in the tapinarof group. The cream also showed promise in reducing itch, with greater reductions in itch reported in the tapinarof group compared to the control group. The safety profile of tapinarof was generally consistent with its use in plaque psoriasis, and there were no reports of contact dermatitis in the AD trials. The manufacturer of tapinarof plans to file for FDA approval for AD in early 2024. [Extracted from the article]

The European Commission has approved lebrikizumab for the treatment of moderate-to-severe atopic dermatitis (AD) in patients aged 12 years and older who have failed topical therapies. Lebrikizumab selectively targets interleukin-13 and inhibits its signaling pathway. The approval was based on data from three pivotal phase 3 studies, which showed significant clinical efficacy of lebrikizumab compared to placebo. Lebrikizumab will first be available in Germany, with a rollout in other European countries expected through 2024. The drug remains under review in the United States. [Extracted from the article]

A study published in JAMA Dermatology has found that dupilumab, a treatment for atopic dermatitis (AD), can cause a benign reversible lymphoid reaction (LR) that mimics mycosis fungoides (MF), a type of cutaneous T-cell lymphoma. The study recommends careful diagnosis of AD, monitoring of patients on dupilumab for new symptoms, and thorough evaluation of suspicious LRs. The study also highlights the importance of distinguishing between AD and MF, as well as the need for vigilance in ruling out MF in patients on dupilumab. The study suggests that discontinuing dupilumab can lead to resolution of the LR. [Extracted from the article]

The American Academy of Dermatology (AAD) has released updated guidelines for managing atopic dermatitis (AD) in adults when topical treatments are not effective. The guidelines cover approved and off-label uses of systemic therapies and phototherapy, including newer treatments such as biologics and oral Janus kinase (JAK) inhibitors. The guidelines rate the evidence as "strong" for certain treatments, including dupilumab and tralokinumab, and conditionally recommend others, such as phototherapy and cyclosporine. The work group also highlighted the need for further research and larger clinical trials to improve the certainty of evidence for these treatments. [Extracted from the article]

The article focuses on the efficacy of tapinarof cream, an aryl hydrocarbon receptor agonist, for treating atopic dermatitis (AD) in both adults and children as young as 2 years old, based on results from two phase 3 trials. It discusses that tapinarof demonstrated high effectiveness, safety and tolerability; significant improvements in itch control; and a potential alternative to topical corticosteroids for AD management.

The article offers information on the European Commission's approval of lebrikizumab for the treatment of moderate-to-severe atopic dermatitis in patients aged 12 years and older who have not responded to topical therapies. It discusses Lebrikizumab, which selectively targets interleukin-13, demonstrated significant clinical efficacy in pivotal phase 3 studies; and its availability will begin in Germany, with a broader European rollout expected through 2024.

The article present a study revealing that some atopic dermatitis (AD) patients treated with dupilumab may experience a benign reversible lymphoid reaction (LR) resembling mycosis fungoides (MF). Topics include the importance of careful AD diagnosis; monitoring patients on dupilumab for unusual symptoms; and conducting thorough workups for suspicious LRs, emphasizing the need for vigilance and shared decision-making regarding dupilumab use in AD patients.

The article present the American Academy of Dermatology's updated guidelines for managing atopic dermatitis (AD) with phototherapy and systemic therapies in adults. Topics include approved and off-label uses of systemic therapies, phototherapy; the inclusion of new treatments like biologics and oral Janus kinase (JAK) inhibitors; evidence-based recommendations; rating certain treatments as "strong," like dupilumab and tralokinumab; and offering conditional recommendations for other therapies.

In the press release, the company said it would work withthe third-party manufacturer and the FDA to address thefeedback "in order to make lebrikizumab available topatients". Latest News The Food and Drug Administration has issued a completeresponse letter regarding lebrikizumab, aninvestigational biologic for the treatment of adult andadolescent patients with moderate to severe atopicdermatitis, describing concerns about findings madeduring an inspection of a third-party contractmanufacturer that included the "monoclonal antibody drugsubstance" for lebrikizumab, Eli Lilly announced in anOct. [Extracted from the article]

* To evaluate the association between AD and theprevalence and frequency of bullying, researchersanalyzed cross-sectional data from adult caregivers ofU.S. adolescents aged 12-17 years who participated in the2021 National Health Interview Survey. Latest News TOPLINE: Adolescents with atopic dermatitis (AD) experiencebullying significantly more often than their peerswithout AD. [Extracted from the article]

Latest News FROM JAMA DERMATOLOGY The risk for inflammatory bowel disease (IBD) was increasedamong children and adults with atopic dermatitis (AD), with therisk increasing with AD severity, according to data from a largecohort study published recently in JAMA Dermatology. UK general practice cohort AD has been associated with an increasing number ofcomorbidities, including IBD, but studies linking AD with IBD,including UC, have had mixed results, the authors wrote. [Extracted from the article]

Latest News The Committee for Medicinal Products for Human Use(CHMP) of the European Medicines Agency (EMA) hasrecommended marketing authorization of lebrikizumab forthe treatment of adult and adolescent patients withmoderate to severe atopic dermatitis (AD) who arecandidates for systemic therapy. ADvocate 1 and ADvocate 2 evaluated lebrikizumabas monotherapy, while ADhere assessed lebrikizumab incombination with topical corticosteroids (TCS) in adult andadolescent patients with moderate to severe AD. [Extracted from the article]

Latest News Arcutis Biotherapeutics has submitted a supplemental NewDrug Application (sNDA) to the Food and DrugAdministration for roflumilast cream 0.15% for thetreatment of mild to moderate atopic dermatitis (AD) inadults and children aged 6 years and older. Submission of the sNDA is based on positive resultsfrom the Interventional Trial Evaluating Roflumilast Creamfor the Treatment of Atopic Dermatitis (INTEGUMENT-1 andINTEGUMENT-2) trials; two identical Phase 3, vehicle-controlledtrials in which roflumilast cream 0.15% or vehiclewas applied once daily for 4 weeks to individuals 6 years ofage and older with mild to moderate AD involving at least3% body surface area. [Extracted from the article]

The article reports on the marketing authorization recommendation by the European Medicines Agency's Committee for Medicinal Products for Human Use (CHMP) for lebrikizumab, an investigational monoclonal antibody that binds to cytokine interleukin-13, for the treatment of adult and adolescent patients with moderate to severe atopic dermatitis who are candidates for systemic therapy. An overview of studies on lebrikizumab as monotherapy and in combination with topical corticosteroids is provided.

The article offers information on a teledermatology clinic program established in an underserved area of Washington, D.C., to provide care for atopic dermatitis (AD) and alopecia areata, with high patient satisfaction. Topics discussed include the challenges of dermatology deserts in underserved communities; the use of telemedicine to educate and treat patients; and the potential for this model to be replicated in other underserved areas across the U.S.

The article informs the association between atopic dermatitis (AD) and group B streptococcus (GBS) colonization in pregnant women, as suggested by a large cross-sectional study. It discusses pregnant women with a history of AD were found to have a higher likelihood of GBS colonization; shedding light on the microbial changes associated with AD; using data from an administrative database of pregnant women; and also highlighted the increased odds of asthma and seasonal allergies in women with AD.

The article present a study regarding the JAK inhibitors efficacious for atopic dermatitis in Asian patients. It discusses the efficacy of three oral Janus kinase (JAK) inhibitors, abrocitinib, baricitinib and upadacitinib; found that abrocitinib and upadacitinib showed better treatment efficacy compared to baricitinib; and demonstrating significant improvements in skin condition and itch reduction among patients.

The article presents a descriptive study on patients treated with dupilumab for moderate-to-severe atopic dermatitis, where around five percent of patients experienced musculoskeletal (MSK) symptoms, such as enthesitis, arthritis, and tenosynovitis. It mentions the researchers from the United Kingdom characterized this new MSK syndrome and noted that most patients responded well to conservative management approaches.

The article offers information on a post hoc analysis of the JADE EXTEND phase 3 trial, which evaluated the effects of oral abrocitinib in adults with moderate to severe atopic dermatitis (AD) for up to 96 weeks. The analysis found that both younger and older patients treated with abrocitinib showed sustained improvements in skin clearance, itch, and quality of life, with a dose-dependent efficacy up to 96 weeks in the younger age group and up to 48 weeks in the older age group.

The article discusses research presented at the Revolutionizing Atopic Dermatitis conference on the long-term safety of JAK-inhibitors in adolescents with atopic dermatitis (AD). The study evaluated the safety profiles of abrocitinib and upadacitinib in adolescents and found that both medications demonstrated acceptable safety profiles with no significant long-term adverse effects observed in patients with moderate to severe AD.

The article focuses on the long-term safety of JAK inhibitors, specifically abrocitinib and upadacitinib, in adolescents with moderate to severe atopic dermatitis (AD). The topics covered include the acceptable safety profile of abrocitinib in adolescents with over 96 weeks of exposure; the absence of unique safety concerns in adolescents compared to adults; and also mentions the similar safety profile of upadacitinib in adolescents and adults with up to 4 years of treatment..

The article focuses on two studies that demonstrate the efficacy of Lebrikizumab and dupilumab in treating dermatitis on the face, hands and feet. Lebrikizumab showed significant improvement in facial and hand dermatitis in patients with moderate to severe atopic dermatitis, while dupilumab rapidly improved signs, symptoms and quality of life in adults and adolescents with moderate to severe hand and foot dermatitis.

The article focuses on randomized controlled trial in Japan, adding online mindfulness and self-compassion training to usual care, improve the quality of life for adults with atopic dermatitis (AD). It discusses that patients who received mindfulness training in addition to usual care had significant improvements in skin disease-specific quality of life; and improvements in secondary outcomes like severity, itch-related scales, self-compassion & adherence to dermatologist-advised treatments.

The article focuses on the potential hidden allergens in nutritional supplements. It emphasizing the need to consider them as a possible cause of allergic reactions. Topics covered include hidden allergens in various supplements such as vitamins, herbs and spices; the importance of discussing supplement use with healthcare providers; the role of food additives in allergic reactions; and food-additive contact sensitivity in the occurrence of atopic dermatitis (AD) in children.

The article focuses on the evolving study of cutaneous dysbiosis and its clinical implications in dermatology. Topics include the factors contributing to the variability in skin microbiota; the role of microbial diversity in managing atopic dermatitis; and the potential use of prebiotics, probiotics and postbiotics in treating skin conditions.

The article focuses on the clinical implications of recent discoveries about skin dysbiosis. Topics discussed include the factors contributing to the variability in the skin microbiota; the role of microbial diversity in atopic dermatitis; the impact of treatments on the microbiota; and it also discusses about the potential benefits of prebiotics, probiotics and postbiotics in managing skin conditions.